A multi-institutional study of the prevalence of BRCA1 and BRCA2 large genomic rearrangements in familial breast cancer patients by Moon-Woo Seong et al.
Seong et al. BMC Cancer 2014, 14:645
http://www.biomedcentral.com/1471-2407/14/645RESEARCH ARTICLE Open AccessA multi-institutional study of the prevalence of
BRCA1 and BRCA2 large genomic rearrangements
in familial breast cancer patients
Moon-Woo Seong1, Sung Im Cho1, Kyu Hyung Kim2, Il Yong Chung3, Eunyoung Kang2, Jong Won Lee4,
Sue K Park5,6,7, Min Hyuk Lee8, Doo Ho Choi9, Cha Kyong Yom10, Woo-Chul Noh11, Myung Chul Chang12,
Sung Sup Park1, Sung-Won Kim2* and Korean Hereditary Breast Cancer Study GroupAbstract
Background: Large genomic rearrangements (LGRs) in the BRCA1/2 genes are frequently observed in breast cancer
patients who are negative for BRCA1/2 small mutations. Here, we examined 221 familial breast cancer patients from
37 hospitals to estimate the contribution of LGRs, in a nationwide context, to the development of breast cancer.
Methods: Direct sequencing or mutation scanning followed by direct sequencing was performed to screen small
mutations. BRCA1/2 small mutation-negative patients were screened for the presence of LGRs using a multiple
ligation-dependent probe amplification (MLPA) assay.
Results: Using a combined strategy to detect the presence of small mutations and LGRs, we identified BRCA1/2
small mutations in 78 (35.3%) out of 221 familial breast cancer patients and BRCA1 LGRs in 3 (2.1%) out of 143
BRCA1/2 small mutation-negative patients: the deletion of exons 11–13, the deletion of exons 13–15, and whole
gene deletion of exons 1-24. The novel deletion of exons 11–13 is thought to result from a non-homologous
recombination event mediated by a microhomology sequence comprised of 3 or 4 base pairs: c.3416_4357 +
1863delins187 (NG_005905.2: g.33369_44944delins187).
Conclusions: In this study, we showed that LGRs were found in 3.7% (3/81) of the patients who had mutations in
BRCA1 or BRCA2, and 7.5% (3/40) of patients with mutations in BRCA1. This suggests that the contribution of LGRs
to familial breast cancer in this population might be comparable to that in other ethnic populations. Given these
findings, an MLPA to screen for mutations in the BRCA1 gene is recommended as an initial screening test in highly
selective settings.
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BRCA1 and BRCA2 are the two major genes that con-
tribute to the development of hereditary breast cancer.
Mutations in these two genes are observed in 15–20% of
hereditary breast cancer cases but less than 5% of overall
breast cancer cases [1,2]. Most BRCA1 or BRCA2 gene
aberrations are small mutations involving a single or mul-
tiple changes in nucleotide sequence, but large genomic* Correspondence: brcakorea@gmail.com
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unless otherwise stated.rearrangements (LGRs) have also been reported in pa-
tients who are negative for BRCA1 or BRCA2 sequence
variations. The prevalence of LGRs varies according to the
ethnicity and selection criteria of the study population
[3,4]. In certain studies conducted in the Netherlands and
Italy, it was shown that in breast and/or ovarian cancer
patients who tested negative for BRCA1 or BRCA2 small
mutations, about 20% carried an LGR in 1 of these 2 genes
[5,6], but many other studies reported a prevalence of
under 10% [7,8]. Although the prevalence of LGRs is ex-
pected to be low in the population in this study compared
to other ethnic populations, the findings reported here areLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The study flowchart outlining the number of subjects and the genetic testing approach used in the study. A total of 221 familial
breast cancer patients were included and MLPA analysis was performed for 143 patients who did not have small mutations in the BRCA1/2 genes.
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not known yet in this population [9,10].
Here, we analyzed 221 familial breast and/or ovarian
cancer patients from 37 different hospitals throughout
Korea to estimate the contribution of LGRs to the devel-
opment of breast cancer in a nationwide context.
Methods
Subjects
Patients who fulfilled the following criteria were selected
for this study between February 2006 and November 2011:
female patients with breast cancer diagnosed at any age,
patients with a family history of 2 or more breast cancer
cases or 1 or more ovarian cancer cases. In total, 221 pa-
tients were enrolled from 37 hospitals throughout the
country. The mutational status of the BRCA1 and
BRCA2 genes was determined for all patients by usingTable 1 The characteristics of the BRCA1 gene in the 3 patien
Patient Deleted exons (size) Nomenclature Mechanis
P1 Exons 11–13 (11,389 bp) c.3416_4357+ 1863delins187 Alu/non-Alu
P2 Exons 13–15 (11,467 bp) c.4186-1593_4676-1465del Alu/Alu H
P3 Whole gene – NA
Abbreviation: NHE, non-homologous event; HR, homologous recombination; NA, nothe following approaches: direct sequencing (155 pa-
tients), or mutation scanning including fluorescence-
based conformation-sensitive gel electrophoresis (F-CSGE)
and denaturing high-performance liquid chromatography
(dHPLC) followed by direct sequencing (66 patients)
(Figure 1). In the latter approach, direct sequencing
was performed when a patient was found to be positive
using the F-CSGE or dHPLC (14 patients) methods;
direct sequencing was otherwise carried out for the en-
tire gene (52 patients). Excluding the 78 patients who
had mutations identified by any of the above ap-
proaches, the remaining 143 patients were screened for
LGRs. All patients received genetic counseling and
BRCA genetic testing was performed after obtaining
informed consent. This study was approved by the in-
stitutional review board of Seoul National University
Bundang Hospital.ts identified with BRCA1 LGRs
m Age at diagnosis Family history Tumor stage IHC
NHE 35 BC+/OC- 0 ER-/PR-/Her2-
R 35 BC+/OC+ IIa ER+/PR+
36 BC+/OC- IIa ER-/PR+/Her2-
t available; BC, breast cancer; OC, ovarian cancer.
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Genomic DNA was extracted from peripheral blood
samples using Gentra PureGene DNA Isolation Kits
(Gentra Systems, Inc. Minneapolis, MN). F-CSGE and
dHPLC were performed as previously described [11].
PCR was performed using primers the flanked the
splice junctions of the coding exons [12]. Amplified
products were sequenced using an ABI 3730 analyzer
(Applied Biosystems, Foster City, CA), with Bigdye Ter-
minator v3.1 Cycle Sequencing Kits. The sequences were
analyzed using SeqScape software (Applied Biosystems,
Foster City, CA) and Mutation Surveyor (Softgenetics,
State College, PA).Figure 2 The 3 BRCA1 LGRs identified in the study using MLPA
screening. The MLPA analysis demonstrates A) exons 11–13 deletion,
B) exons 13–15 deletion, and C) whole gene deletion of exons 1-24.
Exons having a reduced peak ratio are denoted with the arrows.Multiplex ligation-dependent probe amplification (MLPA)
BRCA1 and BRCA2 LGRs were screened using MLPA.
MLPA was performed using the SALSA P002/P002B
BRCA1 Kit (MRC Holland, Amsterdam, Holland) for
BRCA1 and P045/P045B BRCA2 Kit (MRC Holland,
Amsterdam, Holland) for BRCA2. PCR products were
analyzed using an ABI 3100 analyzer with Genemarker
v1.51 (Softgenetics, State College, PA). Peak heights were
normalized, and a deletion or duplication was identified
when the normalized peak ratio value was below 0.75 or
above 1.30.
Characterization of BRCA1 LGR
Long-range PCR was performed with the primers 1 F-
5′-GGAACTAACCAAACGGAGCA-3′ and 1R-5′-AGG
ATTGCTTGAGCCTGAAA-3′ using genomic DNA tem-
plate isolated from patient samples showing a large dele-
tion in exons 11–13. The PCR cycling conditions were as
follows: an initial denaturation at 94°C for 2 min; 10 cycles
at 94°C for 15 s, 65°C for 30 s, and 68°C for 7 min; 25 -
cycles at 94°C for 15 s and 65°C for 30 s; a final extension
at 68°C for 7 min (increase of 20 s per cycle). Amplified
products were sequenced with additional sequencing
primers (4 F-5′-AACCACAGTCGGGAAACAAG-3′, 5 F-
5′- TAGGGGTTTTGCAACCTGAG-3′) using an ABI
3730 analyzer (Applied Biosystems, Foster City, CA) and
analyzed using SeqScape software (Applied Biosystems,
Foster City, CA) and Mutation Surveyor (Softgenetics,
State College, PA). The deletion was described using the
nomenclature used for sequence variations as recommended
by the Human Genome Variation Study (http://www.hgvs.
org/mutnomen); NM_007294.3 was used as the coding
DNA reference sequence.
Statistical analysis
The comparisons between the groups were performed
using the results from Mann-Whitney U tests. Statistical
data was analyzed using SPSS version 16.0 (SPSS, Inc.).
Results
We identified BRCA1/2 small mutations in 78 (35.3%)
out of 221 familial breast cancer patients using direct
sequencing, or mutation scanning including F-CSGE
and dHPLC followed by direct sequencing, and identi-
fied BRCA1 LGRs in 3 (2.1%) out of 143 BRCA1/2 small
mutation-negative patients using MLPA (Figure 1). In
total, the prevalence of BRCA1/2 mutations was 36.7%
(81 of 221) in this study. The prevalence of BRCA1 mu-
tations (49.4%, 40/81) was slightly lower than that of
BRCA2 mutations (50.6%, 41/81). The three different
BRCA1 LGRs identified in the study were as follows: the
deletion of exons 11–13, the deletion of exons 13–15 and
a whole gene deletion of exons 1-24 (Table 1; Figure 2).
Figure 3 A detailed characterization of the deletion of exons 11–13 in the BRCA1 gene identified in patient P1. A) Long-range PCR results
showing an approximately 11 kb-sized deletion in the BRCA1 gene; B) DNA sequence analysis showing that the deletion in the BRCA1 gene in this
case corresponds to NM_007294.3: c.3416_c.4357 + 1863delins187 [NG_005905.2: g.33369_44944delins187]. The 5′ and 3′ breakpoints in the gene
are located within exon 11 and intron 13, respectively, with a partial insertion of intron 12 sequence at the breakpoint (c.4185 + 2603_2789). Short
common sequences (microhomology) are shown shaded in light gray between the rearranged sequences at each breakpoint. MX and MIV:
molecular weight ladders; P1: patient 1; C: healthy control.
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at the age of 35, carries a BRCA1 gene with deletions of
exons 11–13. She had two second-degree relatives with
breast cancer. An immunohistochemistry (IHC) study
revealed that her tumor was negative for ER, PR, and
HER2. The deletion of exons 11–13 was characterized
using long-range PCR and subsequent direct sequencing.
The patient was identified as having a novel, 11,389 bp-
sized deletion that ranged from the base pair at position
681 of the 3′ end of exon 11 to intron 13: c.3416_4357 +
1863delins187 (NG_005905.2: g.33369_44944delins187)
(Figure 3). The 5′ breakpoint was not correlated with
any Alu element, but the 3′ breakpoint was located
within an AluJo element in intron 13. Interestingly, a
partial sequence (187 bp) from intron 12 was inserted
at the deletion site. Both ends of the inserted sequences
showed a 3 base pair (GAA) or 4 base pair (TGTG)
microhomology with the 5′ and 3′ breakpoints, respectively.
Patient P2, who was diagnosed with stage II invasive
ductal carcinoma at the age of 35, carries a BRCA1 gene
lacking exons 13–15 . ER and PR were positive on IHC
staining. The patient has 1 first-degree relative with
ovarian cancer and 1 second-degree relative with breast
cancer. The precise characterization of the deletion
breakpoint in this patient has been previously reported;
this deletion may be the result of Alu-mediated homolo-
gous recombination events [9].Patient P3 was diagnosed with stage II invasive ductal
carcinoma at age 36 and does not have a copy of the
BRCA1 gene. The patient has 4 second-degree relatives
with breast cancer. An IHC study revealed that PR was
positive, and ER and HER2 were negative. The deletion
breakpoint is uncharacterized in this patient.
The mean age at diagnosis of the 3 patients with
BRCA1 LGRs was younger than that of patients with
non-LGR mutations in BRCA1/2 (35.3 vs. 40.7) or
BRCA1 (35.3 vs. 36.8), but these differences were not
statistically significant.
Discussion
To the best of our knowledge, this is the first nationwide
study reporting a screen for BRCA1/2 LGRs in familial
breast and/or ovarian cancer patients in Korea. In this
study, 3 LGRs were identified in 3 out of 143 BRCA1
and BRCA2 small mutation-negative patients. Each pa-
tient had an LGR unique to the family. Furthermore,
LGRs were found only in the BRCA1 gene. The most
common mechanism of LGRs found in BRCA1/2 is
known as the Alu-mediated unequal homologous re-
combination, followed by non-homologous events such
as Alu/non-Alu or non-Alu/non-Alu, and a recombin-
ation event between the BRCA1 gene and a pseudogene
[4]. This mechanism occurs because of the high Alu
density (41.5%) in the BRCA1 gene, which is 4-fold
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observed in the BRCA2 gene [13,14]. Between 2 fully
characterized LGRs in our study, 1 LGR (a deletion of
exons 13–15) might occur because of Alu-mediated
homologous recombination, and the other (a deletion of
exons 11–13) because of non-homologous recombin-
ation events that are mediated by microhomology. Non-
homologous recombination events frequently result in
deletions and short insertions at the site of the deletion
[15]. Interestingly, our case showed a relatively long in-
sertion of 187 bp at the deletion site.
The prevalence of BRCA1 LGRs ranges from approxi-
mately 6%–27% of all mutations detected in the BRCA1
gene; BRCA2 LGRs play a minimal role in breast cancer
[4]. In non-Ashkenazi Jewish families in the United
States, BRCA1 and BRCA2 LGRs comprise 18% (8 of 44)
of all identified mutations; 29% (8 of 28) and 6% (1 of
16) of these mutations occur in the BRCA1 and BRCA2
gene, respectively [16]. Among Asians from Singapore,
LGRs account for 10% (4 of 40) of all mutations and
10.5% (2 of 19) and 9.5% (2/21) in the BRCA1 and
BRCA2 gene, respectively [17]. So far, there have only
been 2 reports describing BRCA1 LGRs in this popula-
tion [9,10]. In the former study, LGRs constituted 2.5%
of all BRCA1/2 mutations and 6.2% of BRCA1 mutations
and LGRs were rarely detected; LGRs were found only
in 1.2% of all BRCA1/2 gene mutations and 2.3% of
BRCA1 gene mutations. Our results demonstrating that
3.7% (3/81) of patients who have mutations in BRCA1/2
and 7.5% (3/40) of patients who have a mutation in the
BRCA1 gene were higher than those reported previously.
Conclusions
This nationwide study suggests that the contribution of
LGRs in the development of familial breast cancer in the
Korean population might be comparable to other ethnic
populations and a MLPA screening for mutations in the
BRCA1 gene is recommended as an initial screening test
in highly selective settings.
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